US › Healthcare

Lyell Immunopharma Inc (LYEL)

US · Healthcare · Biotechnology

$8.12-0.85%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$4,000

Revenue YoY

-50.0%

Net profit

$-44.8M

EPS

$-1.92

EPS estimate

$-1.94

Net margin

-1,118,875.0%

EPS came in at -1.92 against a street estimate of -1.94 — a beat of 1.0%.

Key statistics

Market cap

$213.4M

Forward P/E

0.0

P/B

1.11

Book value

$9.99

EPS (TTM)

$-12.86

52-week high

$45.00

52-week low

$8.21

50-day MA

$12.60

200-day MA

$18.50

Beta

-0.03

Analyst view

Analysts rate Lyell Immunopharma Inc a buy (7 buy, 0 hold, 1 sell out of 8) with an average price target of $37.88.

Shareholding

Insiders

37.31%

Institutions

54.22%

Largest institutional holders

Fund	Stake
ARCH VENTURE CORP	13.25%
GSK PLC	6.17%
Vanguard Capital Management, LLC	3.21%
Orland Properties Ltd	3.08%
BlackRock Inc	2.96%
Almitas Capital LLC	2.37%
Foresite Capital Management V, LLC	1.94%
Millennium Management LLC	1.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lyell Immunopharma Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.